Clinically Meaningful Reduction in Disease Activity Reported with Epratuzumab

San Francisco, October 27, 2008 – Encouraging initial findings from the combined results of two early clinical trials of the drug epratuzumab for lupus were announced by UCB Pharma at the annual meeting of the American College of Rheumatology in San Francisco this week.